HyTest Overview
- Year Founded
-
1994
- Status
-
Acquired/Merged
- Employees
-
112
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
HyTest General Information
Description
Manufacturer of immunological reagents intended for the in vitro diagnostic and research sectors. The company offers monoclonal antibodies, polyclonal antibodies, purified antigens, cardiac markers, infectious disease reagents, inflammation markers, metabolic syndrome reagents, autoimmune disease reagents, veterinary diagnostic reagents, and molecular biology products, enabling its clients to develop accurate assays through high-quality antibodies and antigens.
Contact Information
Website
www.hytest.fi(Operating Subsidiary)
Corporate Office
- Intelligate 1, 6th floor
- Joukahaisenkatu 6
- 20520 Turku
- Finland
Corporate Office
- Intelligate 1, 6th floor
- Joukahaisenkatu 6
- 20520 Turku
- Finland
HyTest Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HyTest Comparisons
Industry
Financing
Details
HyTest Competitors (28)
One of HyTest’s 28 competitors is Aviva Systems Biology, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aviva Systems Biology | Formerly VC-backed | San Diego, CA | ||||
| CaroGen | Venture Capital-Backed | Farmington, CT | ||||
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | ||||
| GeneTex | Formerly VC-backed | Irvine, CA | ||||
| Pacific Immunology | Corporation | Ramona, CA |
HyTest Patents
HyTest Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4752159-A1 | Antibody against estradiol immunocomplex and kit thereof | Pending | 29-Nov-2024 | ||
| JP-2026077630-A | Anti-human immunodeficiency virus type 1 p24 and type 2 p26 antibodies and uses thereof | Pending | 25-Oct-2024 | ||
| EP-4733318-A2 | Antibody against human immunodeficiency virus type 1 p24 and type 2 p26 and uses thereof | Pending | 25-Oct-2024 | ||
| EP-4733318-A3 | Antibody against human immunodeficiency virus type 1 p24 and type 2 p26 and uses thereof | Pending | 25-Oct-2024 | ||
| US-20260118359-A1 | Antibody against human immunodeficiency virus type 1 p24 and type 2 p26 and uses thereof | Pending | 25-Oct-2024 | C07K16/468 |
HyTest Signals
HyTest Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
HyTest FAQs
-
When was HyTest founded?
HyTest was founded in 1994.
-
Where is HyTest headquartered?
HyTest is headquartered in Turku, Finland.
-
What is the size of HyTest?
HyTest has 112 total employees.
-
What industry is HyTest in?
HyTest’s primary industry is Biotechnology.
-
Is HyTest a private or public company?
HyTest is a Private company.
-
What is the current valuation of HyTest?
The current valuation of HyTest is .
-
What is HyTest’s current revenue?
The current revenue for HyTest is .
-
Who are HyTest’s investors?
EQT Credit, HarbourVest Partners, and Summa Equity have invested in HyTest.
-
Who are HyTest’s competitors?
Aviva Systems Biology, CaroGen, Novus Biologicals, GeneTex, and Pacific Immunology are some of the 28 competitors of HyTest.
-
When was HyTest acquired?
HyTest was acquired on 23-Sep-2021.
-
Who acquired HyTest?
HyTest was acquired by Mindray.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process